Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
life sciences
national blog main
national top stories
6
×
clinical trials
boston
san francisco blog main
san francisco top stories
deals
new york blog main
new york top stories
third rock ventures
blackstone group
cancer
cancer drugs
david goldstein
depression
epilepsy
essential tremor
fda
hepatitis b
investing
ipo
kiran reddy
major depressive disorder
perimenopausal depression
praxis precision medicines
revolution medicines
roche
san francisco
sanofi
startups
steven petrou
the column group
venture capital
warp drive bio
alexion pharmaceuticals
aligos therapeutics
What
medicines
6
×
research
6
×
drugs
aims
cancer
disease
drug
ipo
new
praxis
precision
proteins
revolution
stop
way
approach
backed
based
biotech
biotechs
called
cancer’s
caught
cause
causing
central
ceo
cns
debuts
despite
developing
dicerna
disorder
emerged
epigenetic
epigenetics
epilepsy
eye
family
field
Language
unset
Current search:
medicines
×
research
×
" national top stories "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further